Extra citizens come ahead with lawsuits opposed to South Level enterprise | Information

Extra citizens come ahead with lawsuits opposed to South Level enterprise | Information

Nation United States of The united statesUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, Other folks’s Socialist Republic ofAlgeria, Other folks’s Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic…

Read More
South Point business indicted on theft charges | News

South Point business indicted on theft charges | News

Country United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People’s Socialist Republic ofAlgeria, People’s Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People’s…

Read More
POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

POINT Biopharma Reports Fiscal 2021 Financial Results and Provides Business Update

POINT Biopharma Reported 27-patient dosimetry data from the lead-in cohort of the SPLASH trial Randomization phase of SPLASH trial ongoing, top line data expected mid-2023 Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Indianapolis radiopharmaceutical manufacturing facility operational and supplying doses…

Read More
POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs

Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in 2022 from the US Department of Energy Isotope Program to support early-stage pipeline Dosimetry data from the lead-in cohort of the SPLASH trial in mCRPC will be published February 25th in…

Read More